Collaborate with us

Business model

Iconovo focus on the part of the value chain where it can add significant value – the development of the inhalation product, while the customer brings its expertise in performing clinical trials, manufacturing, registration and sales.

Licensing structure

Our customers license exclusive rights to a combination of substance(s) – inhaler – geography. A technology access fee is paid for the exclusive rights. Iconovo develops an inhalation product for the customer and the customer compensates Iconovo by paying development milestones. Once the product is launched, the customer pays Iconovo royalties for the use of licensed intellectual property.

Offerings

Iconovo offers reliable, competitively priced dry powder inhaler solutions based on four proprietary differentiated technical platforms. Collaborating with Iconovo will give the customer a unique inhaler product at reduced project risk, lower development cost and shorter time to market.

Iconovo Product Pipeline

Product candidate	Platform	Indication	Partner	Inhaler development	Formulation development	Clinical / Documentation
Budesonide, formoterol	ICOres™	Asthma, COPD	Amneal	Completed	On-going
Undisclosed substance(s)	ICOres™	Asthma, COPD	Intas	Completed	On-going
No substance	ICOcap™	Asthma, COPD	Stevanato	Completed	Not applicable	On-going
Indacaterol, glycopyrronium	ICOcap™	COPD	BNC Korea (regional)	Completed	On-going
Glycopyrronium	ICOcap™	COPD	BNC Korea (regional)	Completed	On-going
Oxytocin	ICOone™	postpartum hemorrhage	Monash University	Completed	Completed
Spike protein + adjuvant vaccine	ICOone™	Covid-19 infection	Immune System Regulation (ISR)	Completed	On-going
FluticasoneF, vilanterol	ICOpre™	Asthma, COPD	Available for licensing	On-going	On-going
RES030-085	ICOone	Asthma/COPD	Arcede Pharma	Completed	On-going

Amneal collaboration for ICOres

Development of a generic Symbicort ICOres

Development of a generic Symbicort product (budesonide/formoterol) primarily for the European market together with Amneal. The project involves the development of the dry powder formulation and adaptation of the ICOres device. The product has been tested in a pilot pharmacokinetic study. The agreement will generate royalties after launch.

Intas collaboration for ICOres

Development of a generic product in ICOres

Development of a specific generic product in ICOres involving both the development of the dry powder formulation and adaptations to the multi-dose dry powder inhaler ICOres. The product will be used in the treatment of asthma and COPD and is primarily intended for the European market. The agreement will generate royalties after launch.

Stevanato Group collaboration

Global manufacturing, distribution and sales of ICOcap

Stevanato Group, an Italian medical device manufacturer, will manufacture, distribute and sell the inhaler device ICOcap globally. The inhaler is developed by Iconovo. Through the collaboration, ICOcap will be available as an off-the-shelf product that can be purchased by independent drug developers from Stevanato. The agreement will generate royalties after launch.

Monash University collaboration for ICOone

Development of inhaled oxytocin for postpartum hemorrhage

Development of inhaled oxytocin in ICOone for the prevention of postpartum hemorrhage with Monash University supported by a research agreement with J&J. An inhaled formulation provides important advantages such as ease of use, cheaper transport and storage without cold chain and no handling of used needles and syringes. It is particularly important in resource-limited countries. The ultra-low manufacturing cost of the single-use inhaler ICOone is well suited for the project. The project involves the use of a spray-dried formulation in ICOone. The agreement will generate royalties after launch.

BNC Korea collaboration for ICOcap

Development of capsule formulations for ICOcap

Development of two generic capsule formulations for Ultibro Breezhaler (indacaterol/ glycopyrronium) and Seebri Breezhaler (glycopyrronium) for a territory consisting of Korea, Japan, China, Taiwan, Russia, the CIS Countries and the Southeast Asian Countries (including Turkey) together with BNC Korea. The project involves the know-how transfer to manufacture and the exclusive rights to market, sell and distribute the formulations together with ICOcap®. The agreement will generate royalties after launch.

Immune System Regulation (ISR) collaboration for ICOone

Development of inhaled covid-19 vaccine in ICOone

Development of inhaled covid-19 vaccine in ICOone for the prevention of covid-19 viral infections. An inhaled formulation provides important benefits such as ease of use, cheaper transportation, storage without the need for refrigeration and no handling of needles and syringes. Another important benefit is that the vaccine directly reaches the affected area in the pulmonary tissue that will give the needed type of immune response for protection. A single-dose inhaler like ICOone is well suited for the project. The project involves the use of a spray-dried formulation in ICOone. The agreement will generate royalties after launch.

Arcede Pharma collaboration for an inhalation product to treat COPD

Development of RES030-085 in ICOone for phase I studies

Development of an inhalation formulation as well as an inhalation product for phase I studies for the drug candidate RES030-085 for the treatment of COPD and severe asthma. The agreement requires Iconovo to develop a dry powder formulation and an inhalation product based on ICOone. The intention is also to investigate which of Iconovo’s inhalation platforms is best suited for the commercialization of the product. The agreement is a feasibility agreement.